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Introduction 
The Disease: Idiopathic Pulmonary Fibrosis  
Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease with an 
incidence in the United States of 42.7 to 63 per 100,000 and an incidence in Europe of 16.3 to 
17.4 per 100,000 (Nalysnyk et al. 2012). Incidence and severity of IPF increases with age, but on 
average projected survival is just 3-4 years post-diagnosis (Raghu et al. 2014). Until recently, 
treatment options have been limited and mostly palliative, with little impact on survival. For 
many years, the only established treatment shown to extend life was lung transplantation. 
However, lungs are the most difficult organs to transplant, with patients surviving an average of 
just 4.6 years post-transplantation (NIH 2014). Just recently, two drugs (pirfenidone and 
nintedanib) have been approved for treatment of IPF. However, even with such treatments the 
unyielding progression of IPF is only slowed, and a more effective treatment for IPF remains 
both necessary and illusive (as reviewed in Jenkins and Goodwin 2014). 
Fibrosis occurs in organs other than the lungs, including the liver, heart and kidney (He et 
al. 2013). The process is defined by excess connective tissue that spreads throughout the affected 
organ, often leading to organ failure (Ahluwalia et al. 2014). This scarring is caused by abnormal 
proliferation of fibroblasts and accumulation of extracellular matrix (ECM) proteins (Jenkins and 
Goodwin, 2014). Fibroblasts are cells that monitor signals from the ECM and continuously 
remodel the ECM by secreting and rearranging ECM proteins. Fibrosis is a tightly regulated 
process that occurs normally during wound healing and ceases once the wound is healed. The 
progressive scarring characteristic of IPF results from deregulation of the wound healing 
response, leading to damage that reduces the ability of the lungs to exchange oxygen and 
ultimately results in respiratory failure (Jenkins and Goodwin 2014, King Jr et al. 2011).  
Origins of IPF 
 The pathogenesis of IPF is not fully understood, but the predominant theory in the field is 
that fibrosis results from an atypical wound healing response to alveolar epithelial cell injury 
(Jenkins and Goodwin 2014). This includes injuries associated with day-to-day hazards of living, 
including inhalation of dust, aspiration of stomach acid, and viral infection. Injury activates a 
physiological inflammatory response in the lungs, which in turn activates resident fibroblasts 
causing them to divide and secrete ECM proteins. In normal lung repair, the inflammatory 
pathway is shut off when the wound is healed. However, the atypical response observed in IPF 
occurs when the inflammatory response becomes deregulated, resulting in continuous activation 
of fibroblasts and deposition of ECM proteins (reviewed in Ahluwalia et al. 2014 and Jenkins 
and Goodwin 2014). 
The mechanism by which deregulation of the wound healing pathway occurs remains 
unclear; however, it is likely that genetic susceptibility plays a role similar to the one it plays in 
cancer. Familial IPF accounts for only about 20% of all reported cases of IPF, but many sporadic 
cases of IPF have been attributed to mutations in genes involved with host defense, intercellular 
adhesion and DNA repair. Both familial and sporadic IPF have been associated with mutations in 
tumor suppressor genes, indicating that similar factors contribute to the initiation of fibrosis and 
cancer. Other parallels between the fibrosis and cancer are abnormal cell proliferation and global 
suppression of microRNAs involved in cell cycle control. Unlike cancer, fibrosis is not 
metastatic in nature and does not arise from clonal origins (Jenkins and Goodwin 2014). 
 
 
 
Role of the Extracellular Matrix in IPF 
The ECM is composed of proteins and carbohydrates secreted and continuously 
rearranged by fibroblasts (Cox and Erler, 2011). The ECM of the human lung is composed of a 
variety of proteins, including collagen I protein, responsible for tensile strength, as well as 
elastins, laminins and collagen IV (Booth et al. 2012). These proteins serve as a structural 
scaffold on which cells grow and proliferate, and it is their distribution and arrangement that 
determines the macroscopic and microscopic structure of organs. Although the ECM was 
originally thought to be an inert scaffold, it is now being studied as a major regulator of cellular 
function (reviewed in Cox and Erler, 2011). These studies have demonstrated an active role for 
the ECM in wound healing as well as in cancer and fibrosis. 
In IPF, the “stiffness” of the ECM increases due to excessive deposition of collagen I and 
other ECM proteins. Relative stiffness is measured using an indicator of elasticity, the mean 
shear modulus. Physiological lung ECM is compliant, with a median shear modulus of 
approximately 0.5 kilopascals (kPa). In contrast, IPF ECM is relatively stiff, with a median shear 
modulus of approximately 3.0 kPa, with some areas of excess collagen that measure >15 kPa 
(Liu et al. 2010). This stiffness, defined as the ECM’s ability to resist mechanical deformation, 
has been shown to promote lung fibrosis through the regulation of microRNAs (Huang et al. 
2012, Parker et al. 2014).  
One possible mechanism for microRNA regulation is through mechanotransduction 
pathways. Mechanotransduction is a process by which cells can respond to mechanical stimuli 
(i.e. changes in the environment) by transmitting a biochemical signal (Huang et al. 2012). In 
IPF, increased stiffness of the ECM serves as one such mechanical signal, resulting in 
differentiation of fibroblasts into myofibroblasts. Myofibroblasts are fibroblasts that exhibit 
increased motility and ECM reconstitution after injury, and are crucial for initiation and 
progression of fibrosis. A recently published study demonstrates that the activity of transient 
receptor potential vanilloid 4 (TRPV4), a calcium-initiated cation channel, is upregulated in IPF-
derived lung fibroblasts and that TRPV4 knockout prevents fibrosis in mice (Rahaman et al. 
2014). In addition, this study also shows that TRPV4-dependent calcium influx is responsible for 
transmitting the mechanical signal created by fibrotic stiffness and is necessary for myofibroblast 
differentiation (Rahaman et al. 2014). These findings provide evidence for the role of 
mechanotransduction in the initiation of fibrosis; however, the exact mechanism and signaling 
pathway of microRNA regulation by ECM has yet to be thoroughly investigated.  
Role of MicroRNA-29 in IPF 
 MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that act by 
binding to the 3’ untranslated regions of target mRNAs, blocking translation and promoting 
mRNA degradation (He et al. 2013, van Kouwenhove et al. 2011, Mori et al. 2014). Suppression 
of microRNA-29 (miR-29) has been implicated in the initiation and progression of fibrosis in the 
heart, liver, kidney, and lung (He et al. 2013). miR-29 consists of a microRNA family of four 
different transcripts, miR-29a, -29b-1, -29b-2, and -29c. These are transcribed in pairs, with 
miR-29a and -29b-1 located on 7q32.3 and miR-29c and -29b-2 located on 1q32.2. miR-29 
transcripts are initially polycistronic and are later cleaved into their separate mature forms during 
microRNA processing (Mott et al. 2010). The two forms of miR-29b are genetically identical, 
distinguishable only by their chromosomal location and transcriptional pairing. 
miR-29 is negatively regulated by TGF-β/Smad signaling, which has been shown to play 
a role in fibrosis.  Suppression of miR-29 in turn relieves suppression of fibrosis-affiliated genes, 
including collagen I, collagen III, and fibronectin (Xiao et al. 2012). Experiments in Smad3 
knockout mice demonstrate that miR-29 overexpression can prevent and halt progression of 
bleomycin-induced fibrosis (Xiao et al. 2012). This data indicates that suppression of miR-29 in 
fibroblasts may be at least one of the elements responsible for the increased protein production 
observed in IPF. In order to study how a pathological ECM contributes to IPF pathogenesis, our 
group decellularized ECM from control and IPF lung tissue. Results from these experiments 
indicate that IPF ECM in turn suppresses miR-29 expression, establishing a positive feedback 
loop (see Figure 1). This mechanism of positive feedback is a potential factor in the progression 
of fibrosis in IPF (Parker et al. 2014). 
MicroRNA Processing 
As reviewed in He et al. (2013) and Goodall et al. (2013), microRNA processing is 
established as a canonical and highly conserved pathway by which miRNAs are transcribed in 
the nucleus from non-coding regions of DNA, processed, and exported to the cytosol where they 
bind and suppress expression of target mRNA. miRNAs are first transcribed by RNA polymerase 
II as primary miRNAs (pri-miRNAs), which are then capped, spliced and polyadenylated. Pri-
miRNAs spontaneously form hairpin structures, which are recognized by the microprocessor 
complex consisting of Drosha, an RNase III endonuclease, and its binding partner DiGeorge 
syndrome critical region 8 (DGCR8). Drosha cleaves the double-stranded stem of the pri-
miRNA, producing a precursor miRNA (pre-miRNA) that is 60-70 nucleotides long and retains 
its hairpin structure. Two accessory RNA-binding proteins, p68 and p72, are required for 
processing of pri-miRNA to pre-miRNA. Once cleaved, the pre-miRNA molecule is exported to 
the cytoplasm by exportin 5 where it encounters Dicer, another RNA III endonuclease. Dicer 
cleaves the pre-miRNA once more, producing a mature miRNA duplex. Next, an Argonaute 
protein (Ago) unwinds the duplex and the mature single-stranded miRNA is loaded onto the 
RNA-induced silencing complex (RISC). The mature miRNA is capable of binding 
complementary target mRNA and suppresses expression either through translational repression 
or mRNA cleavage and degradation by RISC (see Figure 2).  
The Hippo Pathway: Fibrosis as a Cancer Phenocopy 
As more is discovered about both cancer and IPF, more similarities between the two 
diseases are surfacing. Both cancer and fibrosis exhibit global suppression of microRNA, and in 
cancer there is evidence that this suppression is due to deregulation of the Hippo pathway. 
Cancer cells lose the ability to sense and respond to cell density, resulting in suppression of 
miRNA and an increase in expression of target genes that are involved in cell cycle and cell 
division. This results in increased proliferation leading to tumorigenesis (Mori et al. 2014).  
The Hippo signaling pathway is a tumor-suppressor pathway that regulates microRNA 
processing in a cell-density dependent manner. Physiologically, Hippo signaling helps a cell 
respond to its environment. When cell density is low, the Hippo pathway is off and 
unphosphorylated YAP is able to translocate to the nucleus. Nuclear YAP functions as a 
transcriptional co-activator that regulates expression of target genes associated with increased 
proliferation and oncogenic transformation (Zhao et al. 2008). However, when cell density is 
high, the Hippo pathway is turned on and phosphorylated YAP is prevented from translocating to 
the nucleus, resulting in suppression of genes involved in proliferation. Additionally, the 
localization of YAP is important to microRNA processing because nuclear YAP is able to bind 
to p72, the aforementioned accessory binding protein required for microRNA processing (van 
Kouwenhove et al. 2011). Sequestration of p72 in the nucleus by YAP effectively blocks 
microRNA processing, resulting in an accumulation of pri-miRNA transcripts in the nucleus and 
suppression of mature miRNA in the cytoplasm (see Figure 3) (Mori et al. 2014). 
Although the processes leading to miRNA suppression in fibrosis are not as completely 
understood, it is possible that the Hippo pathway is also involved in initiation and progression of 
fibrosis. The role of the Hippo pathway in fibrosis is implicated by a study demonstrating that 
overexpression of YAP is sufficient to produce fibrosis both in cell culture and in a mouse model 
(Liu et al. 2014). Additionally, we are interested in overexpression of YAP because it is a direct 
target of miR-29 b-1/a (Tumaneng et al. 2012). Involvement of the Hippo pathway in fibrosis 
would help to explain the suppression of miR-29 that has been observed in fibroblasts cultured 
on decellularized IPF ECM tissue (Parker et al. 2014).  
Specific Aims 
(1) Determine whether miR-29 suppression is a cell-inherent trait of fibroblasts isolated from 
IPF patients versus control patients. 
(2) Determine whether miR-29 suppression in IPF is due to inhibition of microRNA 
processing mediated through the Hippo pathway. 
The purpose of this study is to determine unknown players involved in the suppression of miR-
29 observed in IPF. We hypothesize that IPF ECM influences miR-29 suppression by 
deregulating the Hippo pathway in a manner analogous to what has been shown in cancer. 
 
 
 
 
 
 
 
Materials & Methods 
Primary human lung fibroblast cell lines: Cell lines from six donors were isolated from human 
lung tissue obtained from the University of Minnesota’s Tissue Procurement Facility using tissue 
explant methods to isolate fibroblasts. These consist of three control samples derived from 
histologically uninvolved tissue adjacent to a resected tumor and three IPF samples derived from 
regions of the lung that met criteria for interstitial pneumonitis. Patient-derived material was de-
identified and approved for use by University of Minnesota’s Institutional Review Board. Tissue 
was minced and cultivated on 35-mm tissue culture plastic in explant medium (DMEM with 20% 
FBS and 200 IU/mL Streptomycin, 200 IU/mL Penicillin) at 37°C, 95% air/5% CO2 for 2-3 
weeks until confluent. Each cell line was released from the 35-mm plate using trypsin-EDTA 
and allowed to expand in a 150-mm tissue culture dish (considered passage 1) in fibroblast 
growth media (low glucose DMEM, 10% FBS, 100 IU/mL Streptomycin, 100 IU/mL Penicillin). 
Fibroblasts were characterized by their spindle-like morphology, expression of vimentin and 
alpha-smooth muscle actin, and lack of expression of factor VIII and surfactant C (as described 
in Parker et al. 2014). Cells were sub-cultivated at a 1:3 split ratio (37°C, 5% CO2), then frozen 
in 50% fibroblast growth media and 50% freezing media [(20% dimethylsulfoxide (DMSO) in 
fetal bovine serum (FBS)]. All experiments were conducted using freshly activated cell lines 
between passages 4 and 7.  
Decellularized human lung ECM: Human lung tissue (obtained as described in the previous 
section) was cut into 30 cm3 pieces and frozen at -70°C. Frozen tissue adhered to a plate was 
equilibrated to -15°C, cut into 400 µm slices, and frozen (-20°C) in tissue culture dishes 
containing PBS. Tissue was thawed as needed for decellularization and cut into 1 cm2 pieces for 
use. Lung slices were decellularized by 3 overnight wash steps of 1% SDS, 1% Triton-X100, and 
NaCl, lysing any cells remaining on ECM and rinsing away cell remnants in decanted washes (as 
described in Parker et al. 2014). The decellularized ECM that remained was rinsed in PBS and 1 
piece from each patient sample was placed in a 15 mL conical tube with 2 mL antibiotics (200 
IU/mL Streptomycin, 200 IU/mL Penicillin) in PBS and kept at room temperature until ready for 
use (up to 2 hours). Each 15 mL conical tube contained three control or three IPF decellularized 
ECM sections, one from each patient sample. Cells (obtained as described in previous section) 
were released from cell culture dishes using trypsin-EDTA and concentration determined using a 
hemocytometer. PBS containing antibiotics was poured off of the ECM in 15mL conical tubes 
and replaced with 200,000 cells in 2 mL survival media (low glucose DMEM, 1% FBS, 100 
IU/mL Streptomycin, 100 IU/mL Penicillin). Cells were grown for 18 hours oscillating at ~6-8 
revolutions per minute (37°C, 5% CO2/95% air). 
RNA isolation, reverse transcription, and quantitative PCR analysis: After 18 hours of 
incubation, ECM slices containing cells were washed in PBS twice, blotted dry and placed in 1 
mL Tri-Reagent (Sigma-Aldrich) and chloroform extracted. Isolated RNA was reverse 
transcribed using miScript II RT KIT (Qiagen) according to manufacturer’s instructions, 
allowing us to measure mRNA, precursor microRNA, and mature microRNAs from the same 
sample. Because mature microRNA are only around 22 base pairs long and are thus too short to 
be identified using typical 18 base pair primers, the manufacturers developed a universal tag that 
is incorporated into a single round of reverse transcribed complementary DNA product. This 
allows the mature miRNAs to later be detected by a reverse primer complementary to the 
universal tag during qPCR (Qiagen). A primer specific to each mature microRNA sequence is 
also used to identify them from one another. Precursor microRNA were detected using primers 
that recognize the stem loop hairpin structure. All primers used for measuring mature and 
precursor miRNA were proprietary, validated & confirmed by Qiagen (see Table 1 for a list of 
primers used). qPCR was performed using SYBR-Green PCR Kit (Qiagen) and analyzed using a 
Roche Light Cycler 1.5 (Software Version 3.5). Cycle number for each product was normalized 
to RNU (mature) or GAPDH (precursor) and statistics were conducted using a two-tailed student 
t-test.  
Western blot: After 18 hours of incubation, ECM containing cells were washed in PBS twice, 
blotted dry and placed in 125 µL of lysis buffer [150 mM NaCl, 1 mM EGTA, 50 mM Tris, pH 
7.4, 1% Triton X-100, 1% Nonidet P-40, 1% sodium deoxycholate, protease inhibitors (Roche)]. 
Proteins were separated by size using gel electrophoresis on a 10% polyacrylamide gel and were 
then transferred to a nitrocellulose membrane before probing for proteins using specific 
antibodies. The membrane was incubated overnight with primary antibodies at 4°C: rb anti-YAP 
(cell signal 14074; 1:2000), rb anti-GAPDH (Santa Cruz Bio sc-25778; 1:2,000). After 
incubation with primary antibody, the blot was washed three times at room temperature in Tris-
buffered saline with Tween 20 (TBS-T) buffer and incubated in secondary antibody [goat anti-
rabbit IgG horseradish peroxidase (HRP) (Calbiochem 401393; 1:10,000)] at room temperature 
for 1 hour. Washes in TBS-T were repeated and the blot was developed using enhanced 
chemiluminescence (ECL) western blotting detection (GE Healthcare W9488333) following the 
manufacturer’s protocol. 
 
 
 
 
 
Results 
To address the question of whether suppression of miR-29 is an inherent trait in cells 
derived from an IPF patient, levels of mature miR-29 were measured in control and IPF cells 
grown on control and IPF ECM. We chose miR-29a and -29c as readouts of processed 
microRNA as miR-29b is expressed polycistronically with both miR-29a and -29c. miR-214 was 
measured as an internal control as its levels should remain constant in cells grown on control and 
IPF ECM, and is a Hippo pathway non-responsive microRNA (Mori et al. 2014). RNU6 was 
used for normalization because it is a small nuclear RNA found in abundance that is widely used 
as an endogenous control. The results showed that mature miR-29a is suppressed in control 
fibroblasts grown on IPF ECM, but is not significantly decreased in IPF fibroblasts on IPF ECM. 
However, the results for IPF fibroblasts were trending towards significant decrease of miR-29a, 
with one outlying cell line demonstrating increased levels of miR-29a on IPF ECM. Mature miR-
29c is suppressed in both IPF and control fibroblasts on IPF ECM (Figure 1A). These data 
suggest that regulation of miR-29a and -29c is not a cell-inherent trait of IPF fibroblasts. 
To address whether suppression is occurring at the level of microRNA processing, 
precursor miRNA levels for miR-29a and miR-29c were measured, along with precursor miR-
214. GAPDH, another relatively abundant housekeeping gene, was used as a normalization 
control. Precursor miR-29a accumulates only in IPF fibroblasts on IPF ECM, while precursor 
miR-29c does not significantly increase in IPF or control fibroblasts (Figure 1B). These results 
are surprising because suppression of mature forms doesn’t correspond to accumulation of 
precursor forms. Additionally, miR-214, which was included as an unchanging internal control, 
was increased on IPF ECM in control fibroblasts. However, the data for individual cell lines 
trends towards significance for accumulation of precursor miR-29a and -29c, with one major 
outlier in both IPF and control fibroblasts for precursor miR-29c that likely skewed the data. 
Additionally, there is an outlier in the data for precursor miR-214 that may help explain why the 
data shows it is increased in control fibroblasts on IPF ECM. These outliers in individual cell 
lines helps to explain the surprising results and indicate that microRNA processing is likely 
involved in the suppression of miR-29 observed in IPF despite disparities seen in the data.  
The last question raised in this study was whether the Hippo pathway is involved in the 
inhibition of microRNA processing observed in IPF. To address this, a western blot was 
performed to determine if there is an accumulation of YAP in cells on IPF ECM. Five 
independent cell lines (2 IPF and 3 control) were used in this experiment. The results showed 
that there was no significant difference in total YAP levels between control fibroblasts on control 
and IPF ECM. The same was true for IPF fibroblasts (see Figure 5). Although this demonstrates 
that overall YAP levels are the same, it does not take into account the subcellular localization of 
YAP and what impact phosphorylation may have on YAP’s ability to affect microRNA 
processing. 
 
 
 
 
 
 
 
 
 
Discussion 
 Although the downstream effects of miR-29 suppression in fibrosis have been previously 
examined, we still do not understand the mechanism of microRNA suppression in fibrosis. This 
study attempts to address this gap by answering two questions: (1) is miR-29 suppression is a 
cell-inherent trait of IPF fibroblasts and (2) is miR-29 suppression due to inhibition of 
microRNA processing caused by deregulation of the Hippo tumor suppressor pathway. To 
address these questions, we seeded control and IPF fibroblasts on decellularized control and IPF 
ECM and measured the expression of mature and precursor miR-29a and -29c as well as YAP 
protein expression. The results indicate that miR-29 suppression is not a cell-inherent trait of IPF 
fibroblasts and that microRNA processing is inhibited in fibroblasts on IPF ECM (see Figure 
4B).   
Deregulation of the Hippo pathway has been shown to be responsible for miRNA 
suppression and consequent loss of cell density-dependence in cancer (Mori et al. 2014). In this 
study, we hypothesized that deregulation of the Hippo pathway is also responsible for microRNA 
suppression in IPF. From the data, we conclude that inhibition of microRNA processing plays a 
role in miR-29 suppression in cells on IPF ECM, although not to the exclusion of transcriptional 
regulation. It remains unclear, however, if microRNA suppression is due to changes in regulation 
of the Hippo pathway. If this were the case, we would expect to see an accumulation of YAP in 
cells on IPF ECM due to loss of cell density dependence. Our data shows no change in overall 
YAP expression, but does not rule out involvement of the Hippo pathway in fibrosis (see Figure 
5). Thus, further study would be necessary to elucidate the role of the Hippo pathway in miR-29 
suppression in fibrosis. One possibility would be to investigate the phosphorylation state and 
localization of YAP to further examine the Hippo pathway as a regulator of miR-29 expression 
in IPF. Additionally, TAZ, YAP’s co-activation partner, could also be investigated as a player in 
the regulation of microRNA processing.  
If deregulation of the Hippo pathway is not the source of microRNA processing 
inhibition in IPF, it is possible that other downstream regulators of microRNA processing are 
affected. One likely candidate for this is the microprocessor complex, consisting of Drosha and 
DGCR8 as well as p72 and p68, which is responsible for cleaving pri-miRNA to pre-miRNA. 
Another potential candidate is Dicer, which is located in the cytoplasm and cleaves pre-miRNA 
to its mature form. Additionally, there has been some research published implicating down-
regulation of Argonaute proteins in IPF. Argonaute proteins are catalytic subunits that function 
further downstream in microRNA processing, unwinding the microRNA duplex and enabling the 
mature single-stranded microRNA to associate with RISC and thus bind to its target mRNA (see 
Figure 2). Although research has demonstrated Argonaute proteins suppression in IPF, it is not 
clear whether this is due to inhibition at the transcriptional level or to post-transcriptional 
modifications affecting stability and/or activity (Oak et al. 2011). Thus, further research 
investigating the mechanisms behind Argonaute suppression in IPF may further elucidate the 
role of microRNA processing inhibition in miR-29 suppression. 
Although the data presented here do not support our hypothesis that miR-29 suppression 
is due to deregulation of the Hippo tumor suppressor pathway, the results do support our 
hypothesis that suppression is due to inhibition of microRNA processing. Repeating these 
experiments with additional cell lines may yield clearer results from a statistical standpoint.  
Additionally, future studies can look at other components of microRNA processing in order to 
determine the upstream regulators of miR-29 suppression in IPF. This information would lead to 
a better understanding of the disease and better potential targets for treatment of IPF. 
Figures & Tables 
 
 Adapted from Parker et al. (2014). J. Clin. Invest.  
Figure 1: Positive feedback loop between microRNA-29 and the extracellular matrix. This 
figure demonstrates the interaction between miR-29 transcripts and ECM gene expression.  
(L) Increased miR-29 expression represses expression of ECM genes, resulting in physiological 
ECM. (R) Decreased miR-29 expression allows activation of ECM genes, resulting in increased 
protein deposition. This leads to ECM stiffening, greater suppression of miR-29, and further 
activation of ECM gene expression, resulting in a positive feedback loop and spread of fibrosis. 
 
 
 
 
 
Adapted from Goodall et al. (2013) Front Cell Neurosci. 
Figure 2: MicroRNA Processing. Pri-miRNA (the primary microRNA transcript) is transcribed 
from the miRNA gene by RNA polymerase II, cleaved to precursor-miRNA (pre-miRNA) by the 
microprocessor complex and exported to the cytoplasm by exportin 5. In the cytoplasm, Dicer 
cleaves pre-miRNA to a mature miRNA duplex, which is then unwound by an Argonaute protein 
(Ago) and the single-stranded mature miRNA (complementary to target) is loaded onto an RNA-
induced silencing complex (RISC). Together, RISC and the miRNA bind to its target mRNA, 
repressing translation and/or inducing mRNA cleavage and consequent degradation. 
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 Adapted from Mori et al. (2014.) Cell.  
Figure 3: Hippo signaling regulation of microRNA expression. Yes-associated protein 
(YAP), a downstream target of the Hippo signaling pathway, plays a role in regulation of 
microRNA processing. (L) At physiological low cell density, the Hippo pathway is off. YAP is 
unphosphorylated and is able to translocate to the nucleus where it sequesters the accessory 
binding protein p72, effectively preventing microRNA processing. This leads to an accumulation 
of nonfunctional pri-miRNA and a decrease in the amount of mature miRNA, resulting in 
increased expression of genes involved in proliferation. (R) At physiological high cell density the 
Hippo pathway is on. YAP is phosphorylated and sequestered in the cytoplasm, allowing p72 to 
associate with the microprocessor complex and progression of microRNA processing, 
demonstrated by an increase in levels of mature microRNA. This results in a decrease in 
proliferation (contact inhibition).  
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 Figure 4: IPF ECM suppresses mature miR-29 and increases precursor miR-29 
independent of cell type (Averages). 3 control lung fibroblast cell lines and 3 IPF lung 
fibroblast cell lines were cultured on control or IPF ECM for 18 hours and qPCR performed. The 
averages of 3 cell lines are shown, with error bars representing standard error. *P < 0.05 versus 
cells on control ECM, calculated using a two-tailed student t-test. (A) Mature miR-29a, -29c, and 
-214 normalized to RNU6. (B) Precursor miR-29a, -29c, and -214 normalized to GAPDH. 
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 Figure 5: ECM does not regulate YAP abundance. (L) 3 control lung fibroblast cell lines and 
2 IPF lung fibroblast cell lines were cultured on control or IPF ECM for 18 hours. Total cell 
lysates were used for immunoblot probing for YAP and GAPDH. Statistics were performed 
using a two-tailed paired t-test on data normalized to GAPDH and YAP levels in cells on control 
ECM. (Lanes 1-4: Two individual IPF cell lines on control ECM (lanes 1,3) and IPF ECM (2,4). 
Lanes 5-10: Three individual control cell lines on control ECM (5,7,9) and IPF ECM (6,8,10). P 
values calculated using a paired two-tailed student t-test. 
 
 
Table 1: Qiagen primers for qPCR analysis of precursor and mature microRNA probes  
Precursor  Probe sequence data Mature  Probe sequence data 
miR-29b/a MP00001736 miR-29a MS0003262 
miR-29b/c MP00001757 miR-29c MS00003269 
miR-214 MP00001540 miR-214 MS00009093 
GAPDH  QT00079247 RNU6 MS00033740 
RRN18S QT00199367 - - 
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